WO2022089471A1 - ANTIGÈNE MULTIMÈRE DE β-CORONAVIRUS, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION - Google Patents

ANTIGÈNE MULTIMÈRE DE β-CORONAVIRUS, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION Download PDF

Info

Publication number
WO2022089471A1
WO2022089471A1 PCT/CN2021/126639 CN2021126639W WO2022089471A1 WO 2022089471 A1 WO2022089471 A1 WO 2022089471A1 CN 2021126639 W CN2021126639 W CN 2021126639W WO 2022089471 A1 WO2022089471 A1 WO 2022089471A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
betacoronavirus
acid sequence
rbd
antigen
Prior art date
Application number
PCT/CN2021/126639
Other languages
English (en)
Chinese (zh)
Inventor
高福
戴连攀
徐坤
韩雨旋
Original Assignee
中国科学院微生物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国科学院微生物研究所 filed Critical 中国科学院微生物研究所
Publication of WO2022089471A1 publication Critical patent/WO2022089471A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the family Coronaviridae contains four coronavirus genera, namely alpha, beta, gamma, and delta.
  • Severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and new coronavirus (2019-nCoV, later named SARS-CoV-2) are all betacoronaviruses genus. They are both positive-strand RNA enveloped viruses capable of infecting humans and animals widely.
  • the new coronavirus enters cells through human angiotensin-converting enzyme 2 (hACE2), and hACE2 receptors are distributed in arteriovenous endothelial cells, arterial smooth muscle cells, intestinal epithelial cells and alveoli, bronchi and other respiratory organs , the virus can infect these hACE2 receptor-containing cells.
  • hACE2 human angiotensin-converting enzyme 2
  • primary prevention which is the measure taken to the cause when the disease has not yet occurred, and is also the fundamental measure to prevent, control and eliminate the disease
  • secondary prevention is to prevent or slow down the disease during the incubation period.
  • the measures taken to reduce the occurrence of the disease, and the tertiary prevention the measures taken to reduce the harm of the disease during the clinical stage of the disease.
  • primary prevention is the most advanced prevention and the fundamental measure to eliminate the disease
  • beta coronavirus vaccine belongs to primary prevention, so the research and development of beta coronavirus vaccine is very important.
  • S protein Session protein, S
  • E protein envelope protein, E
  • M protein Membrane protein, Membrane protein, M
  • S protein Spike protein, S
  • E protein envelope protein, E
  • M protein Membrane protein, Membrane protein, M
  • RBD receptor binding domain
  • the purpose of this application is to provide a kind of betacoronavirus multimeric antigen, its preparation method and application.
  • tandem two RBDs of betacoronavirus S protein to form a single-chain dimeric RBD protein can be stably expressed.
  • the dimeric RBD protein is more immunogenic than the monomeric RBD protein and can induce more With high antibody levels, this subunit vaccine design strategy is common among betacoronaviruses (PMID: 32645327).
  • This application focuses on the RBD region of betacoronavirus S protein as a vaccine antigen, and constructs an RBD multimer antigen in order to obtain better immune effects.
  • the new coronavirus RBD multimer can be stably expressed, and after immunizing mice, it can induce a strong immune response and produce high neutralizing antibodies. Moreover, the titers of 2019-nCoV neutralizing antibodies produced in mice induced by 2019-nCoV RBD multimers were significantly different from those of 2019-nCoV RBD dimers, indicating that 2019-nCoV multimers improved immunogenicity relative to RBD dimers. , is a good candidate vaccine.
  • a betacoronavirus multimeric antigen its amino acid sequence comprises: a plurality of directly connected in series or by the partial amino acid sequence or the whole amino acid sequence of the receptor binding region of the spike protein of the betacoronavirus connected in series, wherein the series connection
  • the partial amino acid sequence or the entire amino acid sequence of the receptor binding region of the spike protein is from the same betacoronavirus, and the multiple is an integer of ⁇ 3.
  • the partial amino acid sequence or the entire amino acid sequence of the receptor binding region of the tandem spike protein is derived from the same betacoronavirus: the receptor of the tandem spike protein.
  • Part of the amino acid sequence or the entire amino acid sequence of the body binding region is derived from severe respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus or 2019 novel coronavirus.
  • the plurality is 3 or 4.
  • the partial amino acid sequence or the entire amino acid sequence of the receptor binding region of the spike protein of the tandem betacoronavirus is an identical sequence. That is, the tandem sequences are completely identical and are multiple repeating sequences.
  • the connecting amino acid sequences at different positions are independently selected from the following sequences: (GGS) n connecting sequence, wherein n represents the number of GGS, and n is ⁇ 1 ; optionally, n is an integer selected from 1-10; further optionally, n is an integer selected from 1-5.
  • the three letters GGS represent the amino acids G, G, and S, respectively.
  • the linking amino acid sequences at different positions are independent of each other means: the linking amino acid sequence linking the first and second tandem sequences from the N-terminus may be different from the linking amino acid sequences linking the second and third tandem sequences from the N-terminus ,So on and so forth.
  • the partial amino acid sequence of the receptor binding region of the spike protein of betacoronavirus is the entire amino acid sequence of the receptor binding region of the spike protein of betacoronavirus of at least 50%, 60%, 70%, 80%, 90%, 95%, 99%.
  • the partial amino acid sequence or the entire amino acid sequence of the receptor binding region of its spike protein is selected from the group consisting of the following amino acids: Any of the sequences:
  • amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence in (1) the protein encoded by the amino acid sequence has the same or substantially the same immunogenicity as the protein encoded by (1) .
  • the 319-537 region of the receptor binding region of the 2019-nCoV spike protein is derived from the R319-K537 region of the spike protein sequence of the 2019-nCoV WH01 strain (GenBank on NCBI: QHR63250).
  • the amino acid sequence of the betacoronavirus antigen includes any one selected from the following amino acid sequences:
  • the application also provides a method for preparing the above-mentioned betacoronavirus multimeric antigen, comprising the following steps: adding a sequence encoding a signal peptide to the 5' end of the nucleotide sequence encoding the above-mentioned betacoronavirus antigen, and adding a sequence encoding the signal peptide to the 3' end of the nucleotide sequence encoding the above-mentioned betacoronavirus antigen.
  • the sequence encoding the histidine tag and the stop codon are cloned and expressed, the correct recombinants are screened, and then the cells of the expression system are transfected for expression. After the expression, the cell supernatant is collected and purified to obtain the betacoronavirus antigen.
  • the cells of the expression system include mammalian cells, insect cells, yeast cells or bacterial cells, optionally; the mammalian cells include 293T cells or CHO cells, and the Bacterial cells include E. coli cells.
  • the present application also provides a polynucleotide encoding the above-mentioned betacoronavirus multimer antigen, a recombinant vector comprising the above-mentioned polynucleotide, and an expression system cell comprising the above-mentioned recombinant vector.
  • the present application also provides a kind of above-mentioned betacoronavirus multimer antigen, a polynucleotide encoding the above-mentioned betacoronavirus multimer antigen, a recombinant vector comprising the above-mentioned polynucleotide or an expression system cell comprising the above-mentioned recombinant vector in the preparation of betacoronavirus Applications in coronavirus vaccines.
  • the present application also provides a betacoronavirus vaccine, comprising the above-mentioned betacoronavirus multimeric antigen and adjuvant.
  • the adjuvant is selected from aluminum adjuvant, MF59 adjuvant, MF59-like adjuvant or AddaVax TM adjuvant.
  • the present application also provides a betacoronavirus DNA vaccine, comprising: a recombinant vector comprising a DNA sequence encoding the above-mentioned betacoronavirus multimeric antigen.
  • the application also provides a betacoronavirus mRNA vaccine, comprising: a recombinant vector comprising an mRNA sequence encoding the above-mentioned betacoronavirus multimeric antigen.
  • the application also provides a betacoronavirus vector vaccine, which includes: a recombinant viral vector comprising a nucleotide sequence encoding the above-mentioned betacoronavirus multimeric antigen; optionally, the viral vector is selected from the following one Or several kinds: adenovirus vector, poxvirus vector, influenza virus vector, adeno-associated virus vector, vesicular stomatitis virus vector (Vesicular Stomatitis Virus, VSV).
  • Figure 1 shows the novel coronavirus RBD monomer (nCoV-RBD-monomer), dimer (nCoV-RBD-dimer), trimer (nCoV-RBD-trimer) and tetramer (nCoV-RBD-trimer) in Example 1 of the present application -RBD-tetramer) Western Blot.
  • Figure 2 is the molecular sieve analysis and gel electrophoresis analysis of the nCoV-RBD-trimer new crown RBD trimer protein in Example 2 of the present application.
  • Figure 3 is a molecular sieve analysis and gel electrophoresis analysis of the nCoV-RBD-tetramer new crown RBD tetrameric protein in Example 2 of the present application.
  • Figure 4 is the affinity measurement of hACE2 and nCoV-RBD monomers in Example 3 of the present application.
  • the Time (S) value of the abscissa is 400
  • the response value of the ordinate is from high to low
  • the corresponding samples hACE2 proteins of different concentrations
  • They are 800nM, 400nM, 200nM, 100nM, 50nM, 25nM, 12.5nM, 6.25nM, 3.125nM, 1.156nM, 0.78nM, respectively.
  • Figure 5 is the affinity determination of hACE2 and nCoV-RBD-trimer in Example 3 of the present application.
  • the Time (S) value of the abscissa is 400
  • the response value of the ordinate is from high to low
  • the corresponding samples hACE2 proteins of different concentrations
  • They are 800nM, 400nM, 200nM, 100nM, 50nM, 25nM, 12.5nM, 6.25nM, 3.125nM, 1.156nM, 0.78nM, respectively.
  • Figure 6 is the affinity determination of hACE2 and nCoV-RBD tetramer in Example 3 of the present application.
  • the Time (S) value of the abscissa is 400
  • the response value of the ordinate is from high to low
  • the corresponding samples were 800nM, 400nM, 200nM, 100nM, 50nM, 25nM, 12.5nM, 6.25nM, 3.125nM, 1.156nM, 0.78nM, respectively.
  • FIG. 7 is a flow chart of immunizing mice in Example 4 of the present application.
  • Figure 8 is a graph showing the results of the neutralizing antibody titer against the new coronavirus pseudovirus induced after the 35th day in Example 5 of the present application.
  • Example 1 Design of novel coronavirus RBD homotrimers and tetramers
  • trimer and tetramer we designed is: (1) The three new coronavirus RBD sequences (319-537) are connected in series (SEQ ID NO.1), and the N-terminal is connected to the signal peptide (MIHSVFLLMFLLTPTES, SEQ ID NO.
  • nCoV-RBD-trimer (2) The four new coronavirus RBD sequences (319- 537) Concatenation (SEQ ID NO.2), N-terminal linking signal peptide (MIHSVFLLMFLLTPTES), C-terminal adding 6 histidines (HHHHHH) and stop codon, the resulting construction is named nCoV-RBD-tetramer.
  • a new coronavirus RBD sequence (319-541) (SEQ ID NO.3), the N-terminal linking signal peptide (MFVFLVLLPLVSSQC, SEQ ID NO.3) NO.11), 6 histidines (HHHHHH) and a stop codon were added to the C-terminus, and the resulting construction was named nCoV-RBD-monomer;
  • the two new coronavirus RBD sequences (319-537) were connected in series ( SEQ ID NO.4), N-terminal linking signal peptide (MIHSVFLLMFLLTPTES), C-terminal adding 6 histidines (HHHHHH) and stop codon, the resulting construction was named nCoV-RBD-dimer.
  • the open reading frame (including signal peptide, His tag and stop codon) encoding nCoV-RBD-trimer was optimized according to human codons to obtain the DNA sequence (SEQ ID NO.5), and the open reading frame encoding nCoV-RBD-tetramer was The frame (including signal peptide, His tag and stop codon) was optimized according to human codons to obtain the DNA sequence (SEQ ID NO.
  • DNA sequence (SEQ ID NO.7) the open reading frame (including signal peptide, His tag and stop codon) encoding nCoV-RBD-monomer was codon) according to human codon optimization to obtain the DNA sequence (SEQ ID NO.7), and the open reading frame (including signal peptide, His tag and stop codon) encoding nCoV-RBD-dimer is obtained according to human codon optimization
  • the DNA sequence (SEQ ID NO.8), the upstream of the ORF of the encoding gene contains the Kozak sequence gccgccacc, and then these four genes were synthesized and cloned into the pCAGGS vector in Goldwisdom, to obtain the plasmids expressing trimeric RBD and tetrameric RBD pCAGGS-nCoV-RBD-trimer, pCAGGS-nCoV-RBD-tetramer, and plasmids pCAGGS-nCoV-monomer, pCA
  • the above four plasmids pCAGGS-nCoV-trimer, pCAGGS-nCoV-tetramer, pCAGGS-nCoV-monomer and pCAGGS-nCoV-dimer were transfected into HEK293T cells, and the cell supernatant was collected 72 hours later and detected by Western Blot.
  • the primary antibody is a rabbit polyclonal antibody against the new coronavirus RBD protein, the concentration is 1.19mg/mL, the working concentration is 1000 times diluted, the company: Yiqiao Shenzhou; the secondary antibody is HRP-conjugated Affinipure Goat Anti Rabbit IgG ( H+L), company: Proteintech, product number: SA00001-2, working concentration 2000 times dilution), the results are shown in Figure 1, Figure 1 shows: cells can stably express new coronavirus RBD trimer, RBD tetramer, RBD Monomeric, RBD dimer protein.
  • Example 2 Expression and purification of nCoV-RBD-trimer and nCoV-RBD-tetramer
  • Plasmids pCAGGS-nCoV-trimer and pCAGGS-nCoV-tetramer were transfected into HEK293T cells, respectively. After 72 hours, the supernatant was collected, centrifuged to remove the precipitate, and then filtered through a 0.22 ⁇ m filter to further remove impurities. The cell supernatant was adsorbed through a nickel affinity column (Histrap, GE Healthcare) at 4°C. Washing with buffer A (20 mM Tris, 150 mM NaCl, pH 8.0) removes non-specifically bound proteins.
  • buffer B (20 mM Tris, 150 mM NaCl, pH 8.0, 300 mM imidazole) to elute the target protein from the Histrap, and use a 30 kD concentrating tube to concentrate the eluate to buffer A by more than 30 times, and the final volume is less than 1ml.
  • the target protein was further purified by molecular sieve chromatography on a Superdex TM 200Increase 10/300GL column (GE Healthcare).
  • the molecular sieve chromatography buffer was PBS buffer (8 mM Na 2 HPO 4 , 136 mM NaCl, 2 mM KH 2 PO 4 , 2.6 mM KCl, pH 7.2).
  • nCoV-RBD-trimer After molecular sieve chromatography, nCoV-RBD-trimer has an elution peak at around 13-14ml ( Figure 2), and SDS-PAGE analysis shows that the protein is both non-reducing (without DTT) and reducing (with DTT) conditions. About 75KD ( Figure 2), the size of the trimer. nCoV-RBD-tetramer has an elution peak at around 12-13ml ( Figure 3). SDS-PAGE analysis shows that the protein is about 100KD under both non-reducing (without DTT) and reducing (with DTT) conditions (Figure 3). ), is the tetramer size.
  • Example 3 Affinity experiment of the interaction between the novel coronavirus RBD trimeric protein and RBD tetrameric protein and hACE2 protein
  • the protein used in the experiment was changed to (10 mM Na 2 HPO 4 ; 2 mM KH 2 PO 4 , pH 7.4; 137 mM NaCl; 2.7 mM KCl; 0.005% (v/v) Tween-20) by concentrated centrifugation.
  • hACE2 protein was used as the mobile phase, according to 800nM, 400nM , 200nM, 100nM, 50nM, 25nM, 12.5nM, 6.25nM, 3.125nM, 1.156nM, 0.78nM times diluted mobile phase protein, flow through the chip with different concentrations of mobile phase protein in turn, and record the real-time response value.
  • the data was processed by BIAevaluation Version 4.1 (GE Healthcare) software, and the affinity of the new coronavirus RBD monomer, trimer and tetramer protein and hACE2 protein was calculated.
  • nCoV-RBD-trimer and nCoV-RBD-tetramer to hACE2 are comparable to that of 2019-nCoV RBD monomer and hACE2, indicating that nCoV-RBD-trimer and nCoV-RBD-tetramer can also better expose receptor binding Motifs (receptor binding motifs, RBMs).
  • mice with purified RBD trimer, RBD tetramer, RBD monomer, and RBD dimer proteins.
  • the BALB/c mice used were purchased from Viton Lever Company, and they were all female and 7 weeks old.
  • the groups of mice (6 mice in each group) and vaccine doses are shown in Table 1, and the immunization flow chart is shown in Figure 7.
  • the immunization group of the mouse immunization experiment set up the new coronavirus RBD trimeric protein and RBD tetrameric protein (obtained in Example 2) as immunogens, and the control group was nCoV-RBD monomer, RBD dimer protein and PBS respectively as a negative control.
  • mice were immunized with the mixed vaccine, 6 mice per group.
  • the experimental process of mice is shown in Figure 7. All mice were immunized for the first time and the second time on day 0 and day 21, respectively, and each time was intramuscularly injected with 100 ⁇ l of antigen adjuvant mixture (50 ⁇ L immunogen + 50 ⁇ L adjuvant). agent mix). On the 35th day, orbital blood was collected and the serum was collected by centrifugation, stored in a -80°C refrigerator, and then used to detect pseudovirus neutralizing antibody titers.
  • Example 5 Neutralization experiment to detect the level of neutralizing antibodies against the new coronavirus pseudovirus after vaccine immunization
  • the antibody titer value was defined as the highest dilution multiple of the serum whose reaction value was less than 10% of the negative control value, namely the neutralizing antibody NT90.
  • the response value of the lowest dilution factor detection limit
  • the titer of the sample was defined as half of the lowest dilution factor.
  • Figure 8 shows the results of the neutralizing antibody titers of the mouse serum after the second immunization against the new coronavirus pseudovirus detected by the microneutralization assay.
  • Figure 8 shows that nCoV-RBD-trimer and nCoV-RBD-tetramer can induce higher neutralizing antibodies against 2019-nCoV pseudovirus after secondary immunization.
  • Figure 8 shows that the tetrameric nCoV-RBD-tetramer induced a neutralizing antibody level of about 1:104 against the 2019- nCoV pseudovirus, which was not significantly higher than the neutralizing antibody level induced by the trimeric nCoV-RBD-trimer immunized group.
  • the neutralizing antibody induced by the dimer was significantly increased (ns represented P>0.05) (*** represented P ⁇ 0.001), which was significantly higher than that of the monomer nCoV-RBD-monomer.
  • the neutralizing antibody level induced by the monomer was significantly increased (**** represents P ⁇ 0.0001), which was significantly higher than the neutralizing antibody level induced by the PBS control immunization group (**** represents P ⁇ 0.0001).
  • the new coronavirus RBD trimer and the new coronavirus RBD tetramer can be stably expressed, and after immunizing mice, a strong immune response can be induced, and a high level of neutralizing antibodies to the new coronavirus can be produced.
  • the neutralizing antibody titers induced by the new coronavirus RBD trimer and the new coronavirus RBD tetramer in mice were significantly different from those of the new coronavirus RBD dimer, indicating that the new coronavirus RBD trimer and the new coronavirus RBD tetramer Compared with the RBD dimer, the immunogenicity is improved and is a good candidate for the vaccine.
  • the single-chain dimer RBD protein can be stably expressed by tandem two RBDs of the coronavirus.
  • the dimer RBD protein is more immunogenic than the monomer RBD protein and can induce higher antibody levels.
  • this subunit vaccine design strategy is common among betacoronaviruses (PMID: 32645327), so here we found that SARS-CoV-2 RBD trimeric and tetrameric immunized mice induced higher levels of neutralizing antibodies than dimeric RBD Higher (with significant differences), this strategy of RBD trimers and tetramers is likely to be general in subunit vaccine design of other betacoronaviruses (eg, MERS virus, SARS virus, etc.).
  • the novel coronavirus RBD multimer of the present application can be stably expressed, and after immunizing mice, it can induce a strong immune response and produce high neutralizing antibodies. Moreover, the 2019-nCoV neutralizing antibody titers produced in mice induced by the 2019-nCoV RBD multimers of the present application are significantly different from those of the 2019-nCoV RBD dimer, indicating that the 2019-nCoV multimer has increased relative to the RBD dimer. Immunogenic, is a good candidate vaccine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un antigène multimère de β-coronavirus, son procédé de préparation et son utilisation, la séquence d'acides aminés de l'antigène multimère de β-coronavirus comprenant : certaines séquences d'acides aminés ou toutes les séquences d'acides aminés de domaines de liaison au récepteur (RBD) d'une pluralité de protéines de spicule d'un β-coronavirus, les protéines de spicule formant directement une connexion en série ou étant en série par liaison à des séquences d'acides aminés, les certaines séquences d'acides aminés ou toutes les séquences d'acides aminés des RBD des protéines de spicule connectées en série étant dérivées du même β-coronavirus, et la pluralité étant un nombre entier ≥ 3. Un multimère de SARS-CoV-2 RBD peut être exprimé de manière stable, et une réponse immunitaire peut être fortement induite après l'immunisation de souris ; en outre, un titre d'anticorps neutralisant produit par les souris induites est significativement différent de celui d'un dimère de SARS-CoV-2 RBD.
PCT/CN2021/126639 2020-10-27 2021-10-27 ANTIGÈNE MULTIMÈRE DE β-CORONAVIRUS, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION WO2022089471A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011165603.9A CN113943373B (zh) 2020-10-27 2020-10-27 一种β冠状病毒多聚体抗原、其制备方法和应用
CN202011165603.9 2020-10-27

Publications (1)

Publication Number Publication Date
WO2022089471A1 true WO2022089471A1 (fr) 2022-05-05

Family

ID=79327239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/126639 WO2022089471A1 (fr) 2020-10-27 2021-10-27 ANTIGÈNE MULTIMÈRE DE β-CORONAVIRUS, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION

Country Status (2)

Country Link
CN (2) CN113943373B (fr)
WO (1) WO2022089471A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114989308A (zh) * 2022-05-12 2022-09-02 中国科学院微生物研究所 新冠病毒嵌合核酸疫苗及其用途
CN115724999A (zh) * 2022-05-11 2023-03-03 中国科学院微生物研究所 串联式杂合三聚体新冠疫苗
WO2024032365A1 (fr) * 2022-08-12 2024-02-15 上海市公共卫生临床中心 Vaccin multivalent recombiant

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113817029B (zh) * 2021-03-31 2022-09-23 国药中生生物技术研究院有限公司 一种新型冠状病毒s-rbd三聚体蛋白疫苗、其制备方法和应用
WO2023025257A1 (fr) * 2021-08-26 2023-03-02 中国科学院微生物研究所 Antigène hétéromultimère de coronavirus bêta, son procédé de préparation et son utilisation
CN115678906B (zh) * 2022-05-12 2023-09-19 中国科学院微生物研究所 经优化的新冠病毒嵌合核酸疫苗及其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555306A (zh) * 2013-09-19 2016-05-04 诺瓦瓦克斯股份有限公司 免疫原性中东呼吸综合征冠状病毒(MERS-CoV)组合物和方法
CN106928326A (zh) * 2015-12-31 2017-07-07 中国科学院动物研究所 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗
US20180334480A1 (en) * 2015-09-17 2018-11-22 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
CN111217919A (zh) * 2020-03-04 2020-06-02 中山大学 一种基于火球菌铁蛋白的新型冠状病毒s蛋白双区域亚单位纳米疫苗
CN111592602A (zh) * 2020-02-10 2020-08-28 中国科学院微生物研究所 一种β冠状病毒抗原、其制备方法和应用
CN112048005A (zh) * 2020-09-04 2020-12-08 江苏省中国科学院植物研究所 新型冠状病毒s蛋白片段多倍体及其制备方法、检测试剂盒、疫苗及药物
CN113292640A (zh) * 2021-06-18 2021-08-24 国药中生生物技术研究院有限公司 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
CN113461787A (zh) * 2021-04-28 2021-10-01 国药中生生物技术研究院有限公司 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
CN113527522A (zh) * 2021-09-13 2021-10-22 深圳市瑞吉生物科技有限公司 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555306A (zh) * 2013-09-19 2016-05-04 诺瓦瓦克斯股份有限公司 免疫原性中东呼吸综合征冠状病毒(MERS-CoV)组合物和方法
US20180334480A1 (en) * 2015-09-17 2018-11-22 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
CN106928326A (zh) * 2015-12-31 2017-07-07 中国科学院动物研究所 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗
CN111592602A (zh) * 2020-02-10 2020-08-28 中国科学院微生物研究所 一种β冠状病毒抗原、其制备方法和应用
CN111217919A (zh) * 2020-03-04 2020-06-02 中山大学 一种基于火球菌铁蛋白的新型冠状病毒s蛋白双区域亚单位纳米疫苗
CN112048005A (zh) * 2020-09-04 2020-12-08 江苏省中国科学院植物研究所 新型冠状病毒s蛋白片段多倍体及其制备方法、检测试剂盒、疫苗及药物
CN113461787A (zh) * 2021-04-28 2021-10-01 国药中生生物技术研究院有限公司 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
CN113292640A (zh) * 2021-06-18 2021-08-24 国药中生生物技术研究院有限公司 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
CN113527522A (zh) * 2021-09-13 2021-10-22 深圳市瑞吉生物科技有限公司 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAI LIANPAN; ZHENG TIANYI; XU KUN; HAN YUXUAN; XU LILI; HUANG ENQI; AN YALING; CHENG YINGJIE; LI SHIHUA; LIU MEI; YANG MI; LI YAN;: "A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS", CELL, ELSEVIER, AMSTERDAM NL, vol. 182, no. 3, 28 June 2020 (2020-06-28), Amsterdam NL , pages 722, XP086239965, ISSN: 0092-8674, DOI: 10.1016/j.cell.2020.06.035 *
MULLIGAN MARK J.; LYKE KIRSTEN E.; KITCHIN NICHOLAS; ABSALON JUDITH; GURTMAN ALEJANDRA; LOCKHART STEPHEN; NEUZIL KATHLEEN; RAABE V: "Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 586, no. 7830, 1 January 1900 (1900-01-01), London, pages 589 - 593, XP037340452, ISSN: 0028-0836, DOI: 10.1038/s41586-020-2639-4 *
TAI WANBO; ZHAO GUANGYU; SUN SHIHUN; GUO YAN; WANG YUFEI; TAO XINRONG; TSENG CHIEN-TE K.; LI FANG; JIANG SHIBO; DU LANYING,; ZHOU : "A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 499, 15 October 2016 (2016-10-15), AMSTERDAM, NL , pages 375 - 382, XP029793275, ISSN: 0042-6822, DOI: 10.1016/j.virol.2016.10.005 *
XIONG XIAOLI; QU KUN; CIAZYNSKA KATARZYNA A.; HOSMILLO MYRA; CARTER ANDREW P.; EBRAHIMI SORAYA; KE ZUNLONG; SCHERES SJORS H. W.; B: "A thermostable, closed SARS-CoV-2 spike protein trimer", NATURE STRUCTURAL & MOLECULAR BIOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 27, no. 10, 31 July 2020 (2020-07-31), New York , pages 934 - 941, XP037263523, ISSN: 1545-9993, DOI: 10.1038/s41594-020-0478-5 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724999A (zh) * 2022-05-11 2023-03-03 中国科学院微生物研究所 串联式杂合三聚体新冠疫苗
CN115724999B (zh) * 2022-05-11 2023-09-19 中国科学院微生物研究所 串联式杂合三聚体新冠疫苗
CN114989308A (zh) * 2022-05-12 2022-09-02 中国科学院微生物研究所 新冠病毒嵌合核酸疫苗及其用途
WO2024032365A1 (fr) * 2022-08-12 2024-02-15 上海市公共卫生临床中心 Vaccin multivalent recombiant

Also Published As

Publication number Publication date
CN113943373A (zh) 2022-01-18
CN115838433A (zh) 2023-03-24
CN113943373B (zh) 2022-09-06

Similar Documents

Publication Publication Date Title
WO2022089471A1 (fr) ANTIGÈNE MULTIMÈRE DE β-CORONAVIRUS, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
CN113230395B (zh) 一种β冠状病毒抗原、β冠状病毒二联疫苗及其制备方法和应用
WO2022262142A1 (fr) Vaccin à base de protéine rbd tripolymère de sars-cov-2 recombinante capable de générer une activité de neutralisation croisée à large spectre, son procédé de préparation et son utilisation
CN111592602B (zh) 一种β冠状病毒抗原、其制备方法和应用
WO2022184027A1 (fr) Nouvel antigène multivalent de coronavirus, son procédé de préparation et son utilisation
WO2022206222A1 (fr) Vaccin à base de protéine s-rbd trimérique contre le nouveau coronavirus, son procédé de préparation et son utilisation
CN113912710B (zh) 抗新型冠状病毒n蛋白的单克隆抗体及其应用
JP6942309B2 (ja) フラビウイルスウイルス様粒子
CN110317267B (zh) 针对狂犬病病毒的双特异性抗体及其用途
WO2021212785A1 (fr) Anticorps monoclonal entièrement humain et son utilisation
WO2024109611A1 (fr) Protéine f de pré-fusion du virus respiratoire syncytial mutant et son utilisation
CN110964104B (zh) 可结合hpv18病毒的蛋白质及其应用
CN114891075B (zh) 一种对新冠病毒s蛋白rbmfp结构域具有结合亲和力的多肽及其应用
JPH08325291A (ja) ハンタウィルス抗原蛋白質およびモノクローナル抗体
EP4313138A1 (fr) Vaccin sous-unitaire contre le sars-cov-2
CN110204613B (zh) 一种针对胡宁病毒的中和抗体、其制备方法及其应用
WO2023025257A1 (fr) Antigène hétéromultimère de coronavirus bêta, son procédé de préparation et son utilisation
CN104774249A (zh) 猪流行性腹泻病毒m蛋白亲和肽及其筛选方法
CN113444155B (zh) MERS-CoV膜蛋白受体结合域二聚体及其编码基因和应用
WO2017206621A1 (fr) Anticorps monoclonal humain neutralisant 8d6 dirigé contre l'infection par le vhc
WO2022148374A1 (fr) Anticorps 76e1 neutralisant entièrement humain à large spectre contre le coronavirus, et utilisation associée
WO2022210830A1 (fr) Anticorps anti-sars-cov-2
US20220251173A1 (en) Anti-hepatitis b virus antibodies and use thereof
CN117050193A (zh) 一种β冠状病毒重组嵌合抗原、其制备方法及应用
WO2022175404A1 (fr) Polypeptides immunogènes et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21885198

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21885198

Country of ref document: EP

Kind code of ref document: A1